Table 2 Comparison of other genetic alterations between AML patients in low and high BDH2 expression groups

NPM1 ^mut

36 (31.85%)

16 (28.07%)

20 (35.71%)

0.271

FLT3- ITD

23 (20.35%)

7 (12.28%)

16 (28.57%)

0.030*

FLT3- TKD

8 (7.08%)

5 (8.77%)

3 (5.36%)

0.338

NPM1^mut/FLT3- ITD^neg

20 (17.70%)

11(19.30%)

9 (16.07%)

0.368

CEBPA ^a

34 (30.09%)

16 (28.07%)

18 (32.14%)

0.444

CEBPA ^{Double mutation}

9 (7.96%)

3 (5.26%)

6 (10.71%)

0.593

IDH1 ^b

3 (3.75 %)

1 (2.56 %)

2 (4.88%)

0.592

IDH2 ^b

8 (10 %)

3 (7.69%)

5 (12.20%)

0.508

DNMT3A ^b

12 (15 %)

10 (25.641%)

2 (4.88%)

0.009*

MLL ^b

7 (8.75%)

3 (7.69%)

4 (9.76%)

0.426

ERG ^c

11.17 (10.26-12.08)

11.60 (10.48-12.72)

10.68 (9.17-12.20)

0.320

MN1 ^c

12.98 (12.28-13.68)

13.35 (12.42-14.28)

12.55 (11.47-13.64)

0.257

miR-181a ^c

3.12 (2.57-3.67)

3.17 (2.35-3.98)

3.07 (2.30-3.84)

0.864

miR-3151 ^c

12.35 (11.90-12.80)

12.18 (11.53-12.84)

12.53 (11.89-13.16)

0.448